Novartis Singapore’s Post

Empowering Innovation: South Korea's Biopharma Industry Set to Soar 🚀🇰🇷 In the dynamic landscape of South Korea's biopharmaceutical industry, a wave of innovation is taking center stage. This article illuminates the strategic initiatives and groundbreaking research propelling South Korea into a prominent position in the global biopharma arena. Noteworthy is the country's commitment to fostering a collaborative ecosystem, where industry leaders, research institutions, and government bodies synergize efforts for transformative advancements. As South Korea invests heavily in cutting-edge technologies, biosimilar development, and novel therapies, it not only strengthens its domestic healthcare landscape but also emerges as a key player in the international biopharmaceutical community. #BiopharmaInnovation #SouthKoreaBiotech #GlobalHealthcareLeadership

Deals and capacity expansions in the CDMO space continue in Q3 2023. - Novo Nordisk partnered with Thermo Fisher's Patheon for manufacturing Wegovy. - EUROAPI bought BianoGMP GmbH to bolster its presence in the growing oligonucleotide market. - Curia, Touchlight tie-up for doggybone DNA; while MilliporeSigma opened new mRNA sites. - Samsung Biologics expanded its agreement with Bristol Myers Squibb for cancer drug substance manufacturing. - WuXi Vaccines, a subsidiary of WuXi Biologics, launched its first standalone plant for jabs in China. - Bora Pharmaceuticals opened a new facility in Taiwan, offering ophthalmic manufacturing services. #pipeline #cdmo #manufacturing #pharmaceuticals #biotech #pharmaceuticalmanufacturing #outsourcing #innovation #management #digitalmarketing #technology #startups #marketing #sales #strategy #networking #pharmacompass View our dashboard: https://lnkd.in/eBVSSy7T Read more at: https://lnkd.in/eMEH-4Mn #PharmaFlow - CDMO Activity Tracker: Novo taps Patheon to augment Wegovy supply; Wuxi sets up standalone vaccine plant - Pharma Data Compilations by PharmaCompass.com

Singapore has recently become a hotbed for biopharma manufacturing. Prior to Covid-19, the only company with a vaccine plant is GSK. Now there's Sanofi, BioNTech SE, WuXi Biologics and Merck establishing their presence in the vaccine industry. Well, it looks like Merck's $500 million expansion in Singapore will not only create more job opportunities, but also increases Merck's manufacturing capacity for vaccines and inhalers which are used to treat a wide range of diseases including cancer, HIV/Aids, Heptatis. But Merck's investment in Singapore speaks alot- this is a good sign that Singapore is becoming a global leader in the biopharmaceutical manufacturing space and is an attractive space for the lifesciences field! #pharmanews #pharma #growth #manufacturing #merck #expansion #biomanufacturing #opportunities #vaccines #opportunities #innovation Gina Yeo Mason & Co

📢 Korean Drugmakers Roar at JPM Unveiling Innovations 📢 Korean drugmakers made a strong impression at the JP Morgan Healthcare Conference. ➕💊 They showcased their innovative pipelines and growth strategies. 🔬 Korean companies like Celltrion and Samsung BioLogics highlighted their advancements in biologic drugs and biosimilars. 💰 They emphasized their potential for partnerships and global market expansion. 🌍 📈 The Korean biopharmaceutical industry is growing rapidly and aims to become a global biotech leader. #BioprocessUpdates #KoreanDrugmakers #JPMorganHealthcareConference #Innovation #BiologicDrugs #Biosimilars #Partnerships #GlobalExpansion #BiopharmaceuticalIndustry #Celltrion #SamsungBioLogics #Advancements #GrowthStrategies #GlobalBiotechLeader #HealthcareIndustry #JPMMoment ▷ Read the full article here: 📎 https://lnkd.in/d-WCAQd6

Top 10 Contract Development and Manufacturing Organizations (CDMO) The global market for outsourced drug development and manufacturing activities is projected to reach $232.59 billion by 2030 1. Lonza Group Basel, Switzerland CHF 6.223 billion ($6.970 billion) 2. Thermo Fisher Scientific Waltham, MA $6.967 billion 3. Catalent Somerset, NJ FY 2023 Revenues: $4.276 billion 4. WuXi Biologics Wuxi, China RMB 15.269 billion ($2.108 billion) 5. Samsung Biologics Incheon, South Korea KRW 2.338 trillion ($1.773 billion) 6. Siegfried Zofingen, Switzerland CHF 1.23 billion ($1.377 billion) 7. Fujifilm Diosynth Biotechnologies College Station, TX Fujifilm Tokyo, Japan ¥ 194.2 billion ($1.314 billion) 8. Recipharm Stockholm, Sweden €1.227 billion ($1.314 billion) 9. Boehringer Ingelheim Ingelheim, Germany €1.024 billion ($1.097 billion) 10. MilliporeSigma Burlington, MA Merck Darnstadt, Germany €956 million ($1.024 million) #opportunities #strategy #programming #design #team #research #data #health #development #collaboration #projects #testing #immunotherapy #cancer #technology #biotechnology #healthcare #medicine #oncology #precisionmedicine #liquidbiopsy #rna #dna #venturecapital #startup #immunooncology #tcells #innovation #growth #tech #lifesciences #biopharma #oncodxrx

Major Breakthrough in Biopharmaceutical Industry: Mubadala Acquires Kilix Bio! In a game-changing move for global healthcare, Mubadala has officially announced its acquisition of Kilix Bio, a leading British biopharmaceutical innovator renowned for its pioneering treatments. This acquisition is not just a transaction; it's a leap towards transforming healthcare solutions on a global scale. Kilix Bio stands at the cutting edge of biopharmaceutical research, dedicating its efforts to conquer some of the most daunting healthcare challenges of our time. Their work in developing groundbreaking treatments is set to receive a significant boost as they join forces with Mubadala. Mubadala's strategic move to integrate Kilix Bio into its portfolio underscores a profound commitment to fostering innovation that addresses critical health issues worldwide. This partnership is poised to accelerate the development and distribution of essential medical solutions, promising a brighter future for communities around the globe. At its core, this acquisition reflects Mubadala's dedication to sectors with deep societal impact, highlighting a strategic path towards sustainable, knowledge-based economic growth. By combining the strengths of Kilix Bio's innovative team with Mubadala's resources, the collaboration is set to pioneer advancements in healthcare. #Biopharmaceuticals #HealthcareInnovation #Mubadala #KilixBio #GlobalHealth #Innovation #SustainableGrowth https://lnkd.in/dau2gQ8Q

2024 unfolds transformative trends in pharmaceuticals! 🌐 From the continued dominance of small molecule drugs to the rise of biologics, personalised medicine, and a focus on emerging markets. Navigating challenges with innovation, the industry is poised for a dynamic journey. 💊✨ #Pharma2024 #Innovation #HealthcareTrends

Innovative drugs are the backbone of medical progress, driving advancements that shape the future of healthcare. 🌟 Today, China's #biopharma ecosystem stands at the forefront of innovation, revolutionizing both academia and industry. The Asia Summit on Global Health (#ASGH2024) has teamed up with The Hong Kong Polytechnic University to present a thought-provoking session: "How Innovative Drugs Impact China's Biopharmaceutical Industry Ecosystem." 💡 Esteemed representatives from leading #pharmaceutical companies will delve into their latest drug breakthroughs, share invaluable insights, and analyze their profound impact on the industry. For more information, click here: https://lnkd.in/dthgkQYW 📝 Or feel free to reach out to Senior Project Manager, Thea Svith: thea.svith@hktdc.org📌 #HealthcareInnovation #BiopharmaRevolution #ASGH2024🌐